Goldberg et al. [23] in a single cohort phase II trial examined pembrolizumab activity in active BM due to NSCLC and reported an IC objective response rate (ORR) of 29.7% in patients with PD-L1 expression ≥1% in their extracranial lesions. This evidence concerns the gene CD274 and non-small cell lung carcinoma.